U.S. Markets close in 15 mins

Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Alliance for Regenerative Medicines’ Seventh Annual Investors Conference

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

The one-day investor conference is unique in the medical and biotech communities as it focuses on fast-paced, concise presentations from more than 35 companies, fitting them all into a single-day conference while allowing incredible opportunities for one-on-one partnering with venture and strategic investors.

Genprex will present at the Seventh Annual ARM Cell & Gene Therapy Investor Day as follows:

Investor Presentation: Concurrent Tracks, Session 3

Date: Thursday, March 21, 2019

Time: 2:30-2:45 p.m. EDT

Room: Main Bar Room

Venue: Metropolitan Club, One East 60th Street, New York, NY 10022

For the first time ever, Genprex – an Austin, Texas and Cambridge, Massachusetts-based biotech company committed to finding new ways to treat cancer – has been invited to present at the conference. Rodney Varner, Genprex’s Chairman and Chief Executive Officer, and Julien Pham, MD, MPH, Genprex’s President and Chief Operating Officer, will attend the conference on behalf of Genprex. Dr. Pham will lead the company’s presentation.

“I’m looking forward to attending Cell & Gene Therapy Investor Day for the first time, with the opportunity to share information about Genprex’s mission and our gene therapy technologies,” said Pham. “With a wide array of companies and industry leaders all presenting in a single day, this conference enables us and the investment community to take the pulse of where the industry is heading. It is an incredible honor to be a part of this event.”

Cell & Gene Therapy Investor Day, produced by the Alliance for Regenerative Medicine (ARM), an international community of companies, non-profit research institutions, patient organizations and other sector stakeholders dedicated to realizing the promise of regenerative medicine – is an annual conference designed to provide institutional, strategic and venture investors with unparalleled insight into financing opportunities for cell and gene therapy-based treatment and tools. Now in its seventh year, Cell & Gene Therapy Investor Day is a special, one-day conference that places an emphasis on brevity in corporate presentations, with more than 35 companies given 15 minutes each to showcase their work. More than 175 active investors and analysts will convene in New York City for the show, which will also feature fireside chats and expert-led panels, offering unprecedented levels of partnership opportunities and insight into present and future of regenerative medicine.

Investors and credentialed media members interested in attending the event should visit ARM’s website to contact the event's team.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc, and LinkedIn at linkedin.com/company/genprex.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the preeminent international organization focused specifically on the issues facing regenerative medicine and advanced therapies. It advocates for progress in gene therapy, cell therapy, and tissue engineering. Working with its members and policymakers, it fosters investment, research and development, and successful commercialization of safe, effective, and transformational therapies for patients around the world.

In its seventh year, the ARM Cell & Gene Therapy Investor Day gives investors unmatched insight into the gene therapy industry. With significant technological advances and a number of recently approved products, the sector is poised for ever-increasing investor and analyst interest, and Cell & Gene Therapy Investor Day serves as the gateway for the investment world into the sector. The event includes clinical and commercial experts on-hand to address specific questions regarding the outlook for products from more than 35 companies, and how this sector is impacting key therapeutic areas including oncology, ophthalmology, rare disease, diabetes, cardiovascular disease, wound healing and tissue repair and neurodegenerative diseases. The program includes talks by key opinion leaders in the industry, analysts closely following the sector.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex on cancer. Risks and uncertainties associated with Genprex and its lead product candidate Oncoprex are described more fully under the caption "Risk Factors" and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190314005055/en/